Ann: Biotron to Present Positive 48 Week Data fro, page-40

re: Ann: Biotron to Present Positive 48 Week ... The issue with this trial is that the PEG/riba arm had a 75% EOTR which is much higher than the 50% that one generally expects in genotype 1 - what this means is the population these patients were drawn from are likely to have a high frequency of IL28B genotype CC, and the patient's genotype may have been the major factor in determining whether EOTR was achieved or not - these data will need to be presented by Biotron. These results are effectively no more informative than the 12 week results, and hence the chance of attracting collaborators is not much greater than it was. The other problem of course is that PEG/riba will no longer be part of SOC within the next 3 years or so, and the relevance of these results to the future direction of HCV treatment remains unclear.